D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder

Matt G. Kushner, Suck Won Kim, Christopher Donahue, Paul Thuras, David Adson, Michael Kotlyar, James McCabe, Jillian Peterson, Edna B. Foa

Research output: Contribution to journalArticlepeer-review

341 Scopus citations


Background: D-cycloserine (DCS), a glutamatergic partial N-methyl-d-aspartate (NMDA) agonist, can facilitate extinction learning related to cued fear in animals and humans. We predicted that DCS would accelerate obsession-related distress reduction in patients with obsessive-compulsive disorder (OCD) undergoing extinction-based exposure therapy. Methods: We administered DCS (125 mg) or placebo in a double-blind fashion to individuals with OCD approximately 2 hours before each exposure session. Results: D-cycloserine decreased both the number of exposure sessions required to achieve clinical milestones and the rate of therapy dropout. After four exposure sessions, patients in the DCS group reported significantly greater decreases in obsession-related distress compared with the placebo group; however, after additional sessions, the placebo group tended to catch up. Conclusions: D-cycloserine augmentation has the potential to increase the efficiency, palatability, and overall effectiveness of standard exposure therapy for OCD.

Original languageEnglish (US)
Pages (from-to)835-838
Number of pages4
JournalBiological psychiatry
Issue number8
StatePublished - Oct 15 2007

Bibliographical note

Funding Information:
This work was supported, in part, by a grant to the first author from the Obsessive-Compulsive Foundation (#450709).


  • Cognitive-behavioral therapy
  • D-cycloserine
  • obsessive-compulsive disorder
  • treatment


Dive into the research topics of 'D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder'. Together they form a unique fingerprint.

Cite this